Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Sep 6;8(49):85838-85857.
doi: 10.18632/oncotarget.20689. eCollection 2017 Oct 17.

Extracts from Hericium erinaceus relieve inflammatory bowel disease by regulating immunity and gut microbiota

Affiliations

Extracts from Hericium erinaceus relieve inflammatory bowel disease by regulating immunity and gut microbiota

Chen Diling et al. Oncotarget. .

Abstract

Hericium erinaceus (HE), a traditional edible mushroom, is known as a medicine food homology to ameliorate gastrointestinal diseases. To investigate whether HE is clinically effective in alleviating inflammatory bowel disease (IBD), HE extracts (polysaccharide, alcoholic extracts and whole extracts were prepared using solvent extraction methods) were administrated for 2 weeks in rats with IBD induced by trinitro-benzene-sulfonic acid (TNBS) enema (150 mg/kg). Significant clinical and histological changes in IBD rats were identified, including damage activity, common morphous and tissue damage index scores in colonic mucosa and myeloperoxidase (MPO) activity. The damage activity, common morphous and tissue damage index scores in colonic mucosa (P <0.05) were improved, MPO activities were decreased. Inflammatory factors were also differentially expressed in colonic mucosa in IBD rats, including serum cytokines, Foxp3 and interleukin (IL)-10 were increased while NF-κB p65 and tumor necrosis factor (TNF)-α were decreased (P <0.05), and T cells were activated (P <0.05), especially in the alcohol extracts-treated group. We also found that the structure of gut microbiota of the H. erinaceus extracts-treated groups changed significantly by compared with the model group. Further studies revealed that the polysaccharides in HE extracts may play a prebiotic role, whereas the alcoholic extracts show bactericidin-like and immunomodulatory effects. Taken together, we demonstrated that H. erinaceus extracts could promote the growth of beneficial gut bacteria and improve the host immunity in vivo IBD model, which shows clinical potential in relieving IBD by regulating gut microbiota and immune system.

Keywords: Hericium erinaceus; anti-inflammatory; gut microbiota; immune-enhancing effect; inflammatory bowel disease.

PubMed Disclaimer

Conflict of interest statement

CONFLICTS OF INTEREST The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1. DAI scores and histopathological changes in the colon of rats in differently treated groups after induction by TNBS
DAI scores were calculated according to the (A) weight loss, stool consistency, and blood in feces, length of the colon, weight of the colon, and the colon index (weight/length), with six rats per group; (B) histopathological changes in the colon. Normal, group without any treatment; model, the TNBS-induced group; WE, the whole extract-treated group after TNBS induction; PE, the polysaccharides extract-treated group after TNBS induction; AE, the alcohol extracts-treated group after TNBS induction. Values are expressed as means ± standard deviation. #P < 0.05 vs the control group, *P < 0.05, **P < 0.01 vs the model group, indicating significant differences compared with the model group.
Figure 2
Figure 2. Effects of H. erinaceus extracts on TNBS-induced rats
Rats in the normal and model groups were induced by TNBS; WE, the whole extract-treated group after TNBS induction; PE, the polysaccharides extract-treated group after TNBS induction; AE, the alcohol extract-treated group after TNBS induction. The positive control group was treated with 100 mg/(kg·day) of 5-aminosalicylic acid. After treatment for 14 days, the cytokines IL-1α (A), IL-2 (B), IL-8 (C), IL-10 (D), IL-11 (E), IL-12 (F), TNF-α (G), TNF-γ (H), VGEF (I), M-CSF (J), MIP-α (K) and MPO (L) were produced. The assays were carried out according to the procedures recommended in the enzyme-linked immunosorbent assay kit manual. Values were means ± standard deviation of three independent experiments. #P < 0.05 vs the normal group, *P < 0.05, **P < 0.01 vs the TNBS-treated group, indicating significant differences compared with the LPS-treated group.
Figure 3
Figure 3. Immunohistochemistry staining of Foxp3, NF-κB p65, TNF-α, and IL-10 in the colons of different experimental groups (×200) in IBD rats
Rats in the normal without nothing treatment, and model groups were induced by TNBS; WE, the whole extract-treated group after TNBS induction; PE, the polysaccharides extract-treated group after TNBS induction; AE, the alcohol extract-treated group after TNBS induction.
Figure 4
Figure 4. The Bray coefficient of cluster analysis and stacked figure of family composition based on the best classification level of the IBD rats induced by TNBS enema
Figure 5
Figure 5. Tree species classification of the differently treated samples from IBD rats induced by TNBS enema
The pie chart of different colors represents different samples in that classification unit. The size of the radius denotes the tag number accounts for the proportion of the total tag; the larger the radius, the higher the abundance. The numbers next to the pie chart represent the percentage of tag number of the percentage of the total tag.
Figure 6
Figure 6. Tags with significant differences in the relative abundance of different grouping distribution of genus in IBD rats induced by TNBS enema
Figure 7
Figure 7. Polysaccharides extracted from H. erinaceus improved the pathological parameters of the TNBS-induced mice
(A) Body weight changes; (B) levels of LPS in serum; (C) levels of cytokines GM-CSF, TNF-γ, IL-10, IL-12, IL-17α, IL-4, TNF-α, and VGEF-α in serum; (D) histopathological changes in the colon; and (E) histopathological changes in the spleen. Control is the normal without any treatments; model (Mice were induced by TNB), model and high-dose antibiotics, polysaccharides [100 mg/(kg · d)], Bifidobacterium, polysaccharides plus high-dose antibiotics, polysaccharides plus Bifidobacterium, Bifidobacterium plus high-dose antibiotics, and polysaccharides plus Bifidobacterium plus high-dose antibiotics.
Figure 8
Figure 8
Immunohistochemistry staining of (A) TNF-α, (B) NF-κB p65, (C) IL-17, (D) Foxp3 and the mean optical density values were used for analyzing the results of immunohistochemistry (E) in the colons of different experimental groups in IBD mice induced by TNBS enema after treatment with polysaccharides extracted from H. erinaceus.
Figure 9
Figure 9
Polysaccharides extracted from H. erinaceus showed a good prebiotic effect on TNBS-induced mice.
Figure 10
Figure 10
Effect of AE on the TNF-α- and LPS-induced Caco-2 cells (A), CD4+CD25+Treg cells in TNBS-induced IBD rats induced by TNBS enema (B), relative abundance of B. friagilis differently treated IBD rats (C), and the relative content of fatty acids in AE from H. erinaceus analysis by GC–MS (D).
Figure 11
Figure 11
Active ingredients and mode of action of H. erinaceus for IBD prevention and treatment.

Similar articles

Cited by

References

    1. Singh D, Srivastava S, Pradhan M, Kanwar JR, Singh MR. Inflammatory bowel disease: pathogenesis, causative factors, issues, drug treatment strategies, and delivery approaches. Crit Rev Ther Drug Carrier Syst. 2015;32:181–214. - PubMed
    1. Burisch J, Munkholm P. The epidemiology of inflammatory bowel disease. Scand J Gastroenterol. 2015;50:942–51. - PubMed
    1. Burisch J. Crohn's disease and ulcerative colitis. Occurrence, course and prognosis during the first year of disease in a European population-based inception cohort. Dan Med J. 2014;61:B4778. - PubMed
    1. D'Incà R, Paccagnella M, Cardin R, Pathak S, Baldo V, Giron MC, Sturniolo GC. 5-ASA colonic mucosal concentrations resulting from different pharmaceutical formulations in ulcerative colitis. World J Gastroenterol. 2013;19:5665–5670. - PMC - PubMed
    1. Bennett AL, Munkholm P, Andrews JM. Tools for primary care management of inflammatory bowel disease: do they exist? World J Gastroenterol. 2015;21:4457–4465. - PMC - PubMed